Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial
The phase 2 CLL2-BAAG trial tested the measurable residual disease (MRD)-guided triple combination of acalabrutinib, venetoclax, and obinutuzumab after optional bendamustine debulking in 45 patients with relapsed/refractory chronic lymphocytic leukemia (CLL). MRD was measured by flow cytometry (FCM;...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
July 18, 2024
|
| In: |
Blood
Year: 2024, Volume: 144, Issue: 3, Pages: 272-282 |
| ISSN: | 1528-0020 |
| DOI: | 10.1182/blood.2023022730 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood.2023022730
|
| Author Notes: | Moritz Fürstenau, Adam Giza, Jonathan Weiss, Fanni Kleinert, Sandra Robrecht, Fabian Franzen, Janina Stumpf, Petra Langerbeins, Othman Al-Sawaf, Florian Simon, Anna-Maria Fink, Christof Schneider, Eugen Tausch, Johannes Schetelig, Peter Dreger, Sebastian Böttcher, Kirsten Fischer, Karl-Anton Kreuzer, Matthias Ritgen, Anke Schilhabel, Monika Brüggemann, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek, Paula Cramer |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1918390584 | ||
| 003 | DE-627 | ||
| 005 | 20250716233559.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250224s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/blood.2023022730 |2 doi | |
| 035 | |a (DE-627)1918390584 | ||
| 035 | |a (DE-599)KXP1918390584 | ||
| 035 | |a (OCoLC)1528019539 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Fürstenau, Moritz |d 1986- |e VerfasserIn |0 (DE-588)1098210042 |0 (DE-627)857493566 |0 (DE-576)469027215 |4 aut | |
| 245 | 1 | 0 | |a Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL |b final efficacy and ctDNA analysis of the CLL2-BAAG trial |c Moritz Fürstenau, Adam Giza, Jonathan Weiss, Fanni Kleinert, Sandra Robrecht, Fabian Franzen, Janina Stumpf, Petra Langerbeins, Othman Al-Sawaf, Florian Simon, Anna-Maria Fink, Christof Schneider, Eugen Tausch, Johannes Schetelig, Peter Dreger, Sebastian Böttcher, Kirsten Fischer, Karl-Anton Kreuzer, Matthias Ritgen, Anke Schilhabel, Monika Brüggemann, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek, Paula Cramer |
| 264 | 1 | |c July 18, 2024 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 24.02.2025 | ||
| 520 | |a The phase 2 CLL2-BAAG trial tested the measurable residual disease (MRD)-guided triple combination of acalabrutinib, venetoclax, and obinutuzumab after optional bendamustine debulking in 45 patients with relapsed/refractory chronic lymphocytic leukemia (CLL). MRD was measured by flow cytometry (FCM; undetectable MRD <10-4) in peripheral blood (PB) and circulating tumor DNA (ctDNA) using digital droplet polymerase chain reaction of variable-diversity-joining (VDJ) rearrangements and CLL-related mutations in plasma. The median number of previous treatments was 1 (range, 1-4); 18 patients (40%) had received a Bruton tyrosine kinase inhibitor (BTKi) and/or venetoclax before inclusion, 14 of 44 (31.8%) had TP53 aberrations, and 34 (75.6%) had unmutated immunoglobulin heavy-chain variable region genes. With a median observation time of 36.3 months and all patients off-treatment for a median of 21.9 months, uMRD <10-4 in PB was achieved in 42 of the 45 patients (93.3%) at any time point, including 17 of 18 (94.4%) previously exposed to venetoclax/BTKi and 13 of 14 (92.9%) with TP53 aberrations. The estimated 3-year progression-free and overall survival rates were 85.0% and 93.8%, respectively. Overall, 585 paired FCM/ctDNA samples were analyzed and 18 MRD recurrences (5 with and 13 without clinical progression) occurred after the end of treatment. Twelve samples were first detected by ctDNA, 3 by FCM, and 3 synchronously. In conclusion, time-limited MRD-guided acalabrutinib, venetoclax, and obinutuzumab achieved deep remissions in almost all patients with relapsed/refractory CLL. The addition of ctDNA-based analyses to FCM MRD assessment seems to improve early detection of relapses. This trial was registered at www.clinicaltrials.gov as #NCT03787264. | ||
| 700 | 1 | |a Giza, Adam |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weiss, Jonathan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kleinert, Fanni |e VerfasserIn |4 aut | |
| 700 | 1 | |a Robrecht, Sandra |e VerfasserIn |4 aut | |
| 700 | 1 | |a Franzen, Fabian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stumpf, Janina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Langerbeins, Petra |e VerfasserIn |4 aut | |
| 700 | 1 | |a Al-Sawaf, Othman |e VerfasserIn |4 aut | |
| 700 | 1 | |a Simon, Florian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fink, Anna-Maria |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schneider, Christof |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tausch, Eugen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schetelig, Johannes |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dreger, Peter |e VerfasserIn |0 (DE-588)1028891881 |0 (DE-627)732699894 |0 (DE-576)376320966 |4 aut | |
| 700 | 1 | |a Böttcher, Sebastian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fischer, Kirsten |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kreuzer, Karl-Anton |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ritgen, Matthias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schilhabel, Anke |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brüggemann, Monika |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stilgenbauer, Stephan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Eichhorst, Barbara |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hallek, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cramer, Paula |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood |d Washington, DC : American Society of Hematology, 1946 |g 144(2024), 3 vom: Juli, Seite 272-282 |h Online-Ressource |w (DE-627)266886647 |w (DE-600)1468538-3 |w (DE-576)075961938 |x 1528-0020 |7 nnas |a Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL final efficacy and ctDNA analysis of the CLL2-BAAG trial |
| 773 | 1 | 8 | |g volume:144 |g year:2024 |g number:3 |g month:07 |g pages:272-282 |g extent:11 |a Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL final efficacy and ctDNA analysis of the CLL2-BAAG trial |
| 856 | 4 | 0 | |u https://doi.org/10.1182/blood.2023022730 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250224 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 1028891881 |a Dreger, Peter |m 1028891881:Dreger, Peter |d 910000 |d 910100 |e 910000PD1028891881 |e 910100PD1028891881 |k 0/910000/ |k 1/910000/910100/ |p 15 | ||
| 999 | |a KXP-PPN1918390584 |e 4671229846 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"family":"Fürstenau","role":"aut","given":"Moritz","display":"Fürstenau, Moritz"},{"role":"aut","given":"Adam","display":"Giza, Adam","family":"Giza"},{"family":"Weiss","display":"Weiss, Jonathan","role":"aut","given":"Jonathan"},{"family":"Kleinert","given":"Fanni","role":"aut","display":"Kleinert, Fanni"},{"role":"aut","given":"Sandra","display":"Robrecht, Sandra","family":"Robrecht"},{"family":"Franzen","display":"Franzen, Fabian","role":"aut","given":"Fabian"},{"family":"Stumpf","display":"Stumpf, Janina","given":"Janina","role":"aut"},{"role":"aut","given":"Petra","display":"Langerbeins, Petra","family":"Langerbeins"},{"family":"Al-Sawaf","role":"aut","given":"Othman","display":"Al-Sawaf, Othman"},{"family":"Simon","display":"Simon, Florian","role":"aut","given":"Florian"},{"family":"Fink","display":"Fink, Anna-Maria","role":"aut","given":"Anna-Maria"},{"given":"Christof","role":"aut","display":"Schneider, Christof","family":"Schneider"},{"role":"aut","given":"Eugen","display":"Tausch, Eugen","family":"Tausch"},{"display":"Schetelig, Johannes","role":"aut","given":"Johannes","family":"Schetelig"},{"display":"Dreger, Peter","role":"aut","given":"Peter","family":"Dreger"},{"display":"Böttcher, Sebastian","given":"Sebastian","role":"aut","family":"Böttcher"},{"family":"Fischer","display":"Fischer, Kirsten","role":"aut","given":"Kirsten"},{"display":"Kreuzer, Karl-Anton","given":"Karl-Anton","role":"aut","family":"Kreuzer"},{"role":"aut","given":"Matthias","display":"Ritgen, Matthias","family":"Ritgen"},{"family":"Schilhabel","display":"Schilhabel, Anke","given":"Anke","role":"aut"},{"display":"Brüggemann, Monika","role":"aut","given":"Monika","family":"Brüggemann"},{"given":"Stephan","role":"aut","display":"Stilgenbauer, Stephan","family":"Stilgenbauer"},{"role":"aut","given":"Barbara","display":"Eichhorst, Barbara","family":"Eichhorst"},{"given":"Michael","role":"aut","display":"Hallek, Michael","family":"Hallek"},{"given":"Paula","role":"aut","display":"Cramer, Paula","family":"Cramer"}],"name":{"displayForm":["Moritz Fürstenau, Adam Giza, Jonathan Weiss, Fanni Kleinert, Sandra Robrecht, Fabian Franzen, Janina Stumpf, Petra Langerbeins, Othman Al-Sawaf, Florian Simon, Anna-Maria Fink, Christof Schneider, Eugen Tausch, Johannes Schetelig, Peter Dreger, Sebastian Böttcher, Kirsten Fischer, Karl-Anton Kreuzer, Matthias Ritgen, Anke Schilhabel, Monika Brüggemann, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek, Paula Cramer"]},"relHost":[{"pubHistory":["1.1946 -"],"title":[{"title":"Blood","subtitle":"journal of the American Society of Hematology","title_sort":"Blood"}],"language":["eng"],"part":{"pages":"272-282","extent":"11","issue":"3","text":"144(2024), 3 vom: Juli, Seite 272-282","year":"2024","volume":"144"},"origin":[{"publisherPlace":"Washington, DC ; Philadelphia, Pa. ; Stanford, Calif.","dateIssuedKey":"1946","publisher":"American Society of Hematology ; Saunders ; HighWire Press","dateIssuedDisp":"1946-"}],"recId":"266886647","type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"Blood online"}],"disp":"Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL final efficacy and ctDNA analysis of the CLL2-BAAG trialBlood","physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["266886647"],"zdb":["1468538-3"],"issn":["1528-0020"]},"note":["Gesehen am 21.04.2023"],"corporate":[{"role":"isb","display":"American Society of Hematology"}]}],"note":["Gesehen am 24.02.2025"],"id":{"eki":["1918390584"],"doi":["10.1182/blood.2023022730"]},"physDesc":[{"extent":"11 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"July 18, 2024","dateIssuedKey":"2024"}],"recId":"1918390584","language":["eng"],"title":[{"subtitle":"final efficacy and ctDNA analysis of the CLL2-BAAG trial","title":"Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL","title_sort":"Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL"}]} | ||
| SRT | |a FUERSTENAUACALABRUTI1820 | ||